Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy

Matthew A. Lunning, Hai lin Wang, Zhen Huan Hu, Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Sairah Ahmed, David B. Miklos, Yi Lin, Brian T. Hill, Armin Ghobadi, Sattva S. Neelapu, Jason Westin, Chrisopher Dieyi, Polly Field, Harry Miao, Shilpa A. Shahani, Anik Patel, Clare Spooner, Christine FuDavid Muramoto, Hairong Xu, Marcelo C. Pasquini

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences